Crescendo Bioscience, Salt Lake City, a wholly owned subsidiary of Myriad Genetics Inc, South San Francisco, has announced that United Rheumatology, a professional organization for rheumatologists, has added Vectra DA to its clinical practice guidelines for adults with rheumatoid arthritis (RA).
The guidelines are designed to assist United Rheumatology healthcare professionals in the diagnosis, treatment, and monitoring of RA, in order to help patients preserve function, optimize the achievement of remission or near remission, improve quality of life, and monitor outcomes in the safest and most cost-effective fashion possible.
Elena Hitraya, MD, PhD, Crescendo Bioscience.
“We are very excited that United Rheumatology has recognized the clinical utility of Vectra DA for adults with RA,” says Elena Hitraya, MD, PhD, chief medical officer at Crescendo Bioscience.
Vectra DA is a multibiomarker blood test shown to predict radiographic progression of RA. The test integrates the concentrations of 12 serum proteins associated with RA disease activity into a single objective score, on a scale of 1 to 100, to help physicians make more informed treatment decisions. The test’s efficacy has been demonstrated in more than 20 studies with more than 3,000 patients.
For more information, visit Crescendo Bioscience.
